Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1990 Nov;49(11):926–928. doi: 10.1136/ard.49.11.926

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.

J A Casas 1, P A Saway 1, I Villarreal 1, C Nolte 1, B L Menajovsky 1, E E Escudero 1, W D Blackburn 1, G S Alarcón 1, C P Subauste 1
PMCID: PMC1004264  PMID: 2256740

Abstract

A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.

Full text

PDF
926

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barton J. C., Saway D. A., Blackburn W. D., Fallahi S., Jakes J. T., Alarcón G. S. Thrombotic thrombocytopenic purpura in systemic sclerosis. J Rheumatol. 1989 Oct;16(10):1400–1401. [PubMed] [Google Scholar]
  2. Burger A. J., Mannino S. 5-Fluorouracil-induced coronary vasospasm. Am Heart J. 1987 Aug;114(2):433–436. doi: 10.1016/0002-8703(87)90517-5. [DOI] [PubMed] [Google Scholar]
  3. Casas J. A., Subauste C. P., Alarcón G. S. A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis. 1987 Oct;46(10):763–767. doi: 10.1136/ard.46.10.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chaudary S., Song S. Y., Jaski B. E. Profound, yet reversible, heart failure secondary to 5-fluorouracil. Am J Med. 1988 Sep;85(3):454–456. doi: 10.1016/0002-9343(88)90615-8. [DOI] [PubMed] [Google Scholar]
  5. Collins C., Weiden P. L. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):733–736. [PubMed] [Google Scholar]
  6. Freeman N. J., Costanza M. E. 5-Fluorouracil-associated cardiotoxicity. Cancer. 1988 Jan 1;61(1):36–45. doi: 10.1002/1097-0142(19880101)61:1<36::aid-cncr2820610108>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Guillevin L., Ortonne J. P. Traitement de la sclérodermie. Ann Med Interne (Paris) 1983;134(8):754–765. [PubMed] [Google Scholar]
  8. Kleiman N. S., Lehane D. E., Geyer C. E., Jr, Pratt C. M., Young J. B. Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med. 1987 Mar;82(3):566–568. doi: 10.1016/0002-9343(87)90465-7. [DOI] [PubMed] [Google Scholar]
  9. Steen V. D., Blair S., Medsger T. A., Jr The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med. 1986 May;104(5):699–705. doi: 10.7326/0003-4819-104-5-699. [DOI] [PubMed] [Google Scholar]
  10. Steen V. D., Medsger T. A., Jr, Rodnan G. P. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982 Nov;97(5):652–659. doi: 10.7326/0003-4819-97-5-652. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES